NEW YORK ( TheStreet) -- Human Genome Sciences Inc (Nasdaq: HGSI) hit a new 52-week low Tuesday as it is currently trading at $7.48, below its previous 52-week low of $7.50 with 2.1 million shares traded as of 2:06 p.m. ET. Average volume has been six million shares over the past 30 days.

Human Genome Sciences has a market cap of $1.61 billion and is part of the health care sector and drugs industry. Shares are down 67.7% year to date as of the close of trading on Monday.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.

TheStreet Ratings rates Human Genome Sciences as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally weak debt management. You can view the full Human Genome Sciences Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.